文献速递肝病

奥贝胆酸治疗非酒精性脂肪性肝炎所致肝硬化前纤维化的REGENERATE试验新疗效与安全性分析结果

Results from a new efficacy and safety analysis of the REGENERATE trial of obeticholic acid for treatment of pre-cirrhotic fibrosis due to non-alcoholic steatohepatitis.
PubMed 文献 · J Hepatol · 2023-07-28

REGENERATE III期试验的共识小组分析验证了奥贝胆酸(OCA)治疗非酒精性脂肪性肝炎(NASH)伴肝硬化前纤维化的18个月肝活检结果。OCA 25 mg组达到纤维化改善≥1期且NASH无恶化的比例为22.4%,安慰剂组为9.6%(p<0.0001)。安全性数据涵盖2477例受试者,OCA总体耐受性良好。

要点

  • OCA 25 mg组纤维化改善≥1期且NASH无恶化的比例为22.4%,安慰剂组为9.6%(p<0.0001)。
  • OCA 25 mg组NASH缓解且纤维化无恶化的比例为6.5%,安慰剂组为3.5%(p=0.093)。
  • 瘙痒是最常见的治疗中出现的不良事件,各组间严重不良事件和死亡发生率无实质差异。

核心结论

  • 这些结果证实了OCA 25 mg的抗纤维化作用,OCA长期给药总体耐受性良好,数据支持在NASH所致肝硬化前肝纤维化患者中具有正向的获益:风险特征。

研究设计与样本

  • III期REGENERATE试验的疗效与安全性分析,数字化全切片图像由三名病理学家组成的小组独立评估,采用NASH临床研究网络评分系统。
  • 预设疗效分析纳入931例受试者,组织学数据在1607例更大规模人群中得到支持,安全性数据纳入2477例受试者。

主要发现

  • OCA 25 mg组达到纤维化改善≥1期且NASH无恶化的比例为22.4%,安慰剂组为9.6%(p<0.0001)。
  • OCA 25 mg组达到NASH缓解且纤维化无恶化的比例为6.5%,安慰剂组为3.5%(p=0.093)。
  • 1607例更大规模人群的组织学数据支持上述结果。
  • 治疗中出现的不良事件、严重治疗中出现的不良事件和死亡的发生率在各治疗组间无实质差异,瘙痒是最常见的治疗中出现的不良事件。
  • 经判定的肝脏、肾脏和心血管事件发生率较低且在各治疗组间相似。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: Obeticholic acid (OCA) is a first-in-class farnesoid X receptor agonist and antifibrotic agent in development for the treatment of pre-cirrhotic liver fibrosis due to non-alcoholic steatohepatitis (NASH). We aimed to validate the original 18-month liver biopsy analysis from the phase III REGENERATE trial of OCA for the treatment of NASH with a consensus panel analysis, provide additional histology data in a larger population, and evaluate safety from >8,000 total patient-years' exposure with nearly 1,000 participants receiving study drug for >4 years. METHODS: Digitized whole-slide images were evaluated independently by panels of three pathologists using the NASH Clinical Research Network scoring system. Primary endpoints were (1) ≥1 stage improvement in fibrosis with no worsening of NASH or (2) NASH resolution with no worsening of fibrosis. Safety was assessed by laboratory values and adverse events. RESULTS: Prespecified efficacy analyses included 931 participants. The proportion of participants achieving a ≥1 stage improvement in fibrosis with no worsening of NASH was 22.4% for OCA 25 mg vs. 9.6% for placebo (p <0.0001). More participants receiving OCA 25 mg vs. placebo achieved NASH resolution with no worsening of fibrosis (6.5% vs. 3.5%, respectively; p = 0.093). Histology data in a larger population of 1,607 participants supported these results. Safety data included 2,477 participants. The incidence of treatment-emergent adverse events (TEAEs), serious TEAEs, and deaths was not substantively different across treatment groups. Pruritus was the most common TEAE. Rates of adjudicated hepatic, renal, and cardiovascular events were low and similar across treatment groups. CONCLUSIONS: These results confirm the antifibrotic effect of OCA 25 mg. OCA was generally well tolerated over long-term dosing. These data support a positive benefit:risk profile in patients with pre-cirrhotic liver fibrosis due to NASH. IMPACT AND IMPLICATIONS: Patients with non-alcoholic steatohepatitis (NASH) often have liver scarring (fibrosis), which causes an increased risk of liver-related illness and death. Preventing progression of fibrosis to cirrhosis or reversing fibrosis are the main goals of drug development for NASH. In this clinical trial of obeticholic acid (OCA) in patients with NASH (REGENERATE), we reaffirmed our previous results demonstrating that OCA was superior to placebo in improving fibrosis using a more rigorous consensus panel analysis of liver biopsies taken at month 18. We also showed that OCA treatment resulted in dose-dependent reductions of serum liver biochemistries and liver stiffness measurements compared with placebo, even in participants in whom histologic fibrosis did not change at 18 months, providing evidence that the benefit of OCA extends beyond what is captured by the ordinal NASH CRN scoring system. OCA was well tolerated with a favorable safety profile supporting a positive benefit: risk profile in patients with pre-cirrhotic liver fibrosis due to NASH.

来源:J Hepatol,查看原文。版权归原作者所有。

引用

  1. Sanyal AJ, Ratziu V, Loomba R, et al. Results from a new efficacy and safety analysis of the REGENERATE trial of obeticholic acid for treatment of pre-cirrhotic fibrosis due to non-alcoholic steatohepatitis. J Hepatol. 2023. PMID: 37517454. doi:10.1016/j.jhep.2023.07.014

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。